Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

Home
/
update
/
details

Tempus Expands Immuno-Oncology Portfolio with AI-Driven Multimodal Immune Profile Algorithmic Tests Launch

NextEdge Admin

17 Jul 2024

2 min 26 sec

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, announced its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). As the first in Tempus' immunotherapy-based portfolio, IPS uses DNA and RNA test results to calculate a score from 0-100, classifying patients as IPS-Low or IPS-High. This pan-cancer laboratory-developed test (LDT) helps identify patients likely to respond to immunotherapy. Available to life sciences partners, IPS will be an add-on option for clinicians ordering Tempus’ xT and xR tests by year-end. Tempus is conducting a retrospective study to evaluate IPS's utility in advanced pan-cancer patients treated with immune checkpoint inhibitors (ICI), with results expected later this year.

Tempus has also licensed a machine-learning-based test from Dr. Timothy A. Chan of Cleveland Clinic, which predicts the efficacy of immune checkpoint blockade using patient-specific data. This test complements Tempus' growing portfolio of immunotherapy biomarkers.

"Immune checkpoint inhibitors have a significant impact on patient outcomes. Our IPS test is the first multimodal algorithm in immunotherapy, offering critical insights for patient care," said Halla Nimeiri, MD, Chief Development Officer at Tempus. Dr. Chan added, "Collaborating with Tempus allows us to develop AI-powered models to identify patients who may benefit from cancer immunotherapies."

Tempus’ AI platform supports personalized treatment selection, joining other tests like HRD, TO, DPYD, and PurISTSM. Tempus aims to provide physicians with tools that continuously learn from collected data, advancing precision medicine. For more information, visit tempus.com/contact-us.